GPC3 and hepatocellular carcinoma: This finding highlights that IL-15 contributes significantly to toxicity in conventional CAR-T cell therapy, consistent with a recent clinical trial involving IL-15-enhanced GPC3-targeting CAR-T cells for the treatment of hepatocellular carcinoma (HCC) patients104.